Psoriasis Clinical Trial

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Summary

This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007 to monitor the long-term safety of biologic drugs used to treat psoriasis. The study used longitudinal data within the registry to track the trends relating to the disease. For the analysis of improvement and patient reported QoL, patients with a minimum of one follow-up visit were included. The index date was defined as the date of initiation of secukinumab treatment, and follow-up visits were at 6-, 12-, 18-, & 24-months post-index.

View Full Description

Full Description

The BADBIR data was current up until the 31st August 2019 for this analysis.

Study period: From 1st July 2015, as secukinumab was included in BADBIR in January 2016 and patients backdated 6 months, to 31st August 2019.

Identification period: From 1st July 2015 to 31st August 2019 was used to identify applicable patients for analysis.

Index date: Initiation of secukinumab treatment within the BADBIR database.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Inclusion criteria for the biologic cohort:

Age ≥18 years at initiation of secukinumab.
At least one follow-up visit post-registry enrollment.
On-label dosing of secukinumab of 300mg.

Inclusion criteria for the PsA biologic cohort:

Age ≥18 years at initiation of secukinumab.
At least one follow-up visit post-registry enrollment.
On-label dosing of secukinumab of 300mg.
Diagnosis of PsA at baseline.

Exclusion Criteria:

- The patient did not meet the criteria stated above.

Study is for people with:

Psoriasis

Estimated Enrollment:

767

Study ID:

NCT05368818

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Novartis Investigative Site
East Hanover New Jersey, 07936, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Estimated Enrollment:

767

Study ID:

NCT05368818

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider